Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A Randomized Clinical Trial
Dagan Coppock, Pierre-Christian Violet, Gustavo Vasquez, Katherine Belden, Michael Foster, Bret Mullin, Devon Magee, Isabelle Mikell, Lokesh Shah, Victoria Powers, Brian Curcio, Daniel Monti, Mark Levine
Life, doi:10.3390/life12030453
Despite the widespread availability of effective vaccines, new cases of infection with severe acute respiratory syndrome coronavirus-2, the cause of coronavirus disease 2019 (COVID-19), remain a concern in the settings of vaccine hesitancy and vaccine breakthrough. In this randomized, controlled, phase 2 trial, we hypothesized that high-dose ascorbic acid delivered intravenously to achieve pharmacologic concentrations may target the high viral phase of COVID-19 and thus improve early clinical outcomes. Sixty-six patients admitted with COVID-19 and requiring supplemental oxygen were randomized to receive either escalating doses of intravenous ascorbic acid plus standard of care or standard of care alone. The demographic and clinical characteristics were well-balanced between the two study arms. The primary outcome evaluated in this study was clinical improvement at 72 h after randomization. While the primary outcome was not achieved, point estimates for the composite outcome and its individual components of decreased use of supplemental oxygen, decreased use of bronchodilators, and the time to discharge were all favorable for the treatment arm. Possible favorable effects of ascorbic acid were most apparent during the first 72 h of hospitalization, although these effects disappeared over the course of the entire hospitalization. Future larger trials of intravenous ascorbic acid should be based on our current understanding of COVID-19 with a focus on the potential early benefits of ascorbic in hospitalized patients.
outcomes during the 72-h window after randomization, consistent with our hypotheses. Further consistent with our hypotheses, these trends were nullified as the curves crossed later in the hospitalization. As secondary endpoints, both the times to discharge and a 50% reduction in oxygenation were statistically non-significant when measured over the entire hospitalization. This pattern was not wholly unexpected. As noted above, an early benefit was consistent with our proposed mechanism of action. Regarding safety, the proportion of patients who experienced a clinical decline in the treatment arm did not meet stopping rules and the trial was continued to its full accrual. Though the point estimates were higher for serious adverse events and clinical decline in the first 36 h, the study was not powered to detect these differences, which were not statistically significant. Our trial had limitations. In retrospect, the study was small with optimistic outcome assumptions. Outcomes in this trial were defined in the early part of the pandemic, and do not reflect our current understanding of COVID-19 as a disease process. Furthermore, our patient risk stratification, while focused on age and comorbidities, may be improved in future studies. An emphasis on more severe underlying metabolic disease (i.e., diabetes), as opposed to any pulmonary or cardiovascular disease, may better improve patient selection and risk analyses. Viral load and specific analyses of lymphocyte populations were..
References
Agarwal, Hager, Sevransky, Any Role of High-Dose Vitamin C for Septic Shock in 2021?, Semin. Respir. Crit. Care Med,
doi:10.1055/s-0041-1733986Baj, Novazzi, Pasciuta, Genoni, Ferrante et al., Breakthrough Infections of E484K-Harboring SARS-CoV-2 Delta Variant, Lombardy, Italy, Emerg. Infect. Dis,
doi:10.3201/eid2712.211792Bergwerk, Gonen, Lustig, Amit, Lipsitch et al., COVID-19 Breakthrough Infections in Vaccinated Health Care Workers, N. Engl. J. Med,
doi:10.1056/NEJMoa2109072Chang, Liao, Guan, Guo, Zhao et al., Combined Treatment With Hydrocortisone, Vitamin C, and Thiamine for Sepsis and Septic Shock: A Randomized Controlled Trial, Chest
Chen, Espey, Krishna, Mitchell, Corpe et al., Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues, Proc. Natl. Acad. Sci,
doi:10.1073/pnas.0506390102Chen, Espey, Sun, Lee, Krishna et al., Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo, Proc. Natl. Acad. Sci,
doi:10.1073/pnas.0702854104Chen, Espey, Sun, Pooput, Kirk et al., Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice, Proc. Natl. Acad. Sci,
doi:10.1073/pnas.0804226105Desai, Neyaz, Szabolcs, Shih, Chen et al., Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection, Nat. Commun,
doi:10.1038/s41467-020-20139-7Fowler, None
Fujii, Luethi, Young, Frei, Eastwood et al., Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock, JAMA,
doi:10.1001/jama.2019.22176Fujii, Salanti, Belletti, Bellomo, Carr et al., Effect of adjunctive vitamin C, glucocorticoids, and vitamin B1 on longer-term mortality in adults with sepsis or septic shock: A systematic review and a component network meta-analysis, Intensiv. Care Med,
doi:10.1007/s00134-021-06558-0Hacisuleyman, Hale, Saito, Blachere, Bergh et al., Vaccine Breakthrough Infections with SARS-CoV-2 Variants, N. Engl. J. Med,
doi:10.1056/NEJMoa2105000Harakeh, Jariwalla, Pauling, Suppression of human immunodeficiency virus replication by ascorbate in chronically and acutely infected cells, Proc. Natl. Acad. Sci,
doi:10.1073/pnas.87.18.7245Hoffer, Levine, Assouline, Melnychuk, Padayatty et al., Phase I clinical trial of i.v. ascorbic acid in advanced malignancy, Ann. Oncol,
doi:10.1093/annonc/mdn377Holmes, Veteran, Center, None
Hwang, Ryoo, Park, Jo, Jang et al., Combination therapy of vitamin C and thiamine for septic shock: A multi-centre, double-blinded randomized, controlled study, Intensiv. Care Med,
doi:10.1007/s00134-020-06191-3Iglesias, Vassallo, Patel, Sullivan, Cavanaugh et al., Outcomes of Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in the Early Treatment of Sepsis: The ORANGES Trial, Chest,
doi:10.1016/j.chest.2020.02.049Jeong, Hong, Kim, Jin, Kang et al., Vitamin C-treated murine bone marrow-derived dendritic cells preferentially drive naïve T cells into Th1 cells by increased IL-12 secretions, Cell. Immunol,
doi:10.1016/j.cellimm.2010.10.005Lahore, Role of Mega Dose of Vitamin C in Critical COVID-19 Patients
Marik, Khangoora, Rivera, Hooper, Catravas, Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock, Chest,
doi:10.1016/j.chest.2016.11.036Mccune, Toepp, Sheehan, Sherani, Petr et al., High dose intravenous vitamin C treatment in Sepsis: Associations with acute kidney injury and mortality, BMC Nephrol,
doi:10.1186/s12882-021-02599-1Menon, Mohamed, Prasannan, Moni, Edathadathil et al., Vitamin C Therapy for Routine Care in Septic Shock (ViCTOR) Trial: Effect of Intravenous Vitamin C, Thiamine, and Hydrocortisone Administration on Inpatient Mortality among Patients with Septic Shock, Indian J. Crit. Care Med,
doi:10.5005/jp-journals-10071-23517Moskowitz, Huang, Hou, Gong, Doshi et al., Effect of Ascorbic Acid, Corticosteroids, and Thiamine on Organ Injury in Septic Shock: The ACTS Randomized Clinical Trial, JAMA,
doi:10.1001/jama.2020.11946Natarajan, Brophy, Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients with Sepsis and Severe Acute Respiratory Failure, JAMA,
doi:10.1001/jama.2019.11825Nauman, Gray, Parkinson, Levine, Paller, Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials, Antioxidants,
doi:10.3390/antiox7070089Research, Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation
Rosengrave, Spencer, Williman, Mehrtens, Morgan et al., Intravenous vitamin C administration to patients with septic shock: A pilot randomised controlled trial, Crit. Care,
doi:10.1186/s13054-022-03900-wSchoenfeld, Sibenaller, Mapuskar, Wagner, Cramer-Morales et al., O2•− and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate, Cancer Cell,
doi:10.1016/j.ccell.2017.07.008Sevransky, Rothman, Hager, Bernard, Brown et al., Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator-and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial, JAMA,
doi:10.1001/jama.2020.24505Solís Arce, Warren, Meriggi, Scacco, Mcmurry et al., COVID-19 vaccine acceptance and hesitancy in low-and middle-income countries, Nat. Med
Thomas, Patel, Bittel, Wolski, Wang et al., Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction among Ambulatory Patients with SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial, JAMA Netw. Open,
doi:10.1001/jamanetworkopen.2021.0369Truwit, Hite, Morris, Dewilde, Priday et al., None
Van Gorkom, Wolterink, Van Elssen, Wieten, Germeraad et al., Influence of Vitamin C on Lymphocytes: An Overview, Antioxidants,
doi:10.3390/antiox7030041Villamañán, Sobrino, Carpio, Moreno, Arancón et al., Inhaled bronchodilators use and clinical course of adult inpatients with Covid-19 pneumonia in Spain: A retrospective cohort study, Pulm. Pharmacol. Ther,
doi:10.1016/j.pupt.2021.102007Wani, Mufti, Jan, Shah, Qadri et al., Combination of vitamin C, thiamine and hydrocortisone added to standard treatment in the management of sepsis: Results from an open label randomised controlled clinical trial and a review of the literature, Infect. Dis,
doi:10.1080/23744235.2020.1718200{ 'indexed': {'date-parts': [[2024, 3, 25]], 'date-time': '2024-03-25T00:48:59Z', 'timestamp': 1711327739272},
'reference-count': 42,
'publisher': 'MDPI AG',
'issue': '3',
'license': [ { 'start': { 'date-parts': [[2022, 3, 19]],
'date-time': '2022-03-19T00:00:00Z',
'timestamp': 1647648000000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0/'}],
'funder': [ { 'DOI': '10.13039/100019408',
'name': 'Marcus Foundation',
'doi-asserted-by': 'publisher',
'award': ['NA']},
{ 'DOI': '10.13039/100000062',
'name': 'National Institute of Diabetes and Digestive and Kidney Diseases',
'doi-asserted-by': 'publisher',
'award': ['DK053212-16']}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'abstract': '<jats:p>Despite the widespread availability of effective vaccines, new cases of infection '
'with severe acute respiratory syndrome coronavirus-2, the cause of coronavirus disease 2019 '
'(COVID-19), remain a concern in the settings of vaccine hesitancy and vaccine breakthrough. '
'In this randomized, controlled, phase 2 trial, we hypothesized that high-dose ascorbic acid '
'delivered intravenously to achieve pharmacologic concentrations may target the high viral '
'phase of COVID-19 and thus improve early clinical outcomes. Sixty-six patients admitted with '
'COVID-19 and requiring supplemental oxygen were randomized to receive either escalating doses '
'of intravenous ascorbic acid plus standard of care or standard of care alone. The demographic '
'and clinical characteristics were well-balanced between the two study arms. The primary '
'outcome evaluated in this study was clinical improvement at 72 h after randomization. While '
'the primary outcome was not achieved, point estimates for the composite outcome and its '
'individual components of decreased use of supplemental oxygen, decreased use of '
'bronchodilators, and the time to discharge were all favorable for the treatment arm. Possible '
'favorable effects of ascorbic acid were most apparent during the first 72 h of '
'hospitalization, although these effects disappeared over the course of the entire '
'hospitalization. Future larger trials of intravenous ascorbic acid should be based on our '
'current understanding of COVID-19 with a focus on the potential early benefits of ascorbic in '
'hospitalized patients.</jats:p>',
'DOI': '10.3390/life12030453',
'type': 'journal-article',
'created': {'date-parts': [[2022, 3, 21]], 'date-time': '2022-03-21T01:30:14Z', 'timestamp': 1647826214000},
'page': '453',
'source': 'Crossref',
'is-referenced-by-count': 12,
'title': 'Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A '
'Randomized Clinical Trial',
'prefix': '10.3390',
'volume': '12',
'author': [ { 'ORCID': 'http://orcid.org/0000-0002-1212-1470',
'authenticated-orcid': False,
'given': 'Dagan',
'family': 'Coppock',
'sequence': 'first',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-9550-3660',
'authenticated-orcid': False,
'given': 'Pierre-Christian',
'family': 'Violet',
'sequence': 'additional',
'affiliation': []},
{'given': 'Gustavo', 'family': 'Vasquez', 'sequence': 'additional', 'affiliation': []},
{'given': 'Katherine', 'family': 'Belden', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0003-3675-8289',
'authenticated-orcid': False,
'given': 'Michael',
'family': 'Foster',
'sequence': 'additional',
'affiliation': []},
{'given': 'Bret', 'family': 'Mullin', 'sequence': 'additional', 'affiliation': []},
{'given': 'Devon', 'family': 'Magee', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-5922-7953',
'authenticated-orcid': False,
'given': 'Isabelle',
'family': 'Mikell',
'sequence': 'additional',
'affiliation': []},
{'given': 'Lokesh', 'family': 'Shah', 'sequence': 'additional', 'affiliation': []},
{'given': 'Victoria', 'family': 'Powers', 'sequence': 'additional', 'affiliation': []},
{'given': 'Brian', 'family': 'Curcio', 'sequence': 'additional', 'affiliation': []},
{'given': 'Daniel', 'family': 'Monti', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-6297-4650',
'authenticated-orcid': False,
'given': 'Mark',
'family': 'Levine',
'sequence': 'additional',
'affiliation': []}],
'member': '1968',
'published-online': {'date-parts': [[2022, 3, 19]]},
'reference': [ { 'key': 'ref1',
'article-title': 'Estimated COVID-19 Burden',
'author': 'Centers for Disease Control and Prevention'},
{'key': 'ref2', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41591-021-01454-y'},
{'key': 'ref3', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2109072'},
{'key': 'ref4', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2105000'},
{'key': 'ref5', 'doi-asserted-by': 'publisher', 'DOI': '10.3201/eid2712.211792'},
{'key': 'ref6', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41467-020-20139-7'},
{'key': 'ref7', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/BF02002847'},
{'key': 'ref8', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cellimm.2010.10.005'},
{'key': 'ref9', 'doi-asserted-by': 'publisher', 'DOI': '10.1073/pnas.87.18.7245'},
{'key': 'ref10', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/antiox7030041'},
{'key': 'ref11', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/14787210.2020.1706483'},
{'key': 'ref12', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/ni1202-1129'},
{ 'key': 'ref13',
'doi-asserted-by': 'publisher',
'DOI': '10.7326/0003-4819-140-7-200404060-00010'},
{'key': 'ref14', 'doi-asserted-by': 'publisher', 'DOI': '10.1073/pnas.0702854104'},
{'key': 'ref15', 'doi-asserted-by': 'publisher', 'DOI': '10.1073/pnas.0804226105'},
{'key': 'ref16', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ccell.2017.03.008'},
{ 'key': 'ref17',
'article-title': 'Adverse Events',
'author': 'Centers for Disease Control and Prevention'},
{ 'key': 'ref18',
'article-title': 'High-Dose Vitamin C Treatment in Critically Ill COVID-19 Patients',
'author': 'Sisli Hamidiye Etfal Training and Research Hospital'},
{ 'key': 'ref19',
'article-title': 'Role of Mega Dose of Vitamin C in Critical COVID-19 Patients'},
{ 'key': 'ref20',
'article-title': 'Hunter Holmes Mcguire Veteran Affairs Medical Center; Mcguire Research '
'Institute, Administration of Intravenous Vitamin C in Novel Coronavirus '
'Infection (COVID-19) and Decreased Oxygenation'},
{'key': 'ref21', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jamanetworkopen.2021.0369'},
{'key': 'ref22', 'doi-asserted-by': 'publisher', 'DOI': '10.1073/pnas.0506390102'},
{'key': 'ref23', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/annonc/mdn377'},
{'key': 'ref24', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/antiox7070089'},
{'key': 'ref25', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ccell.2017.07.008'},
{'key': 'ref26', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2019.22176'},
{'key': 'ref27', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.chest.2020.02.049'},
{'key': 'ref28', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/23744235.2020.1718200'},
{'key': 'ref29', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.chest.2020.02.065'},
{'key': 'ref30', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.11946'},
{'key': 'ref31', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s00134-020-06191-3'},
{'key': 'ref32', 'doi-asserted-by': 'publisher', 'DOI': '10.5005/jp-journals-10071-23517'},
{'key': 'ref33', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.24505'},
{'key': 'ref34', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2019.11825'},
{'key': 'ref35', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s00134-021-06558-0'},
{'key': 'ref36', 'doi-asserted-by': 'publisher', 'DOI': '10.1055/s-0041-1733986'},
{'key': 'ref37', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s13054-022-03900-w'},
{'key': 'ref38', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.chest.2016.11.036'},
{'key': 'ref39', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s12882-021-02599-1'},
{ 'key': 'ref40',
'article-title': 'National Hospital Care Survey',
'author': 'Centers for Disease Control and Prevention'},
{ 'key': 'ref41',
'article-title': 'COVID-19: Developing Drugs and Biological Products for Treatment or '
'Prevention Guidance for Industry',
'author': 'United States Food and Drug Administration'},
{'key': 'ref42', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.pupt.2021.102007'}],
'container-title': 'Life',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.mdpi.com/2075-1729/12/3/453/pdf',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2022, 9, 1]],
'date-time': '2022-09-01T06:44:48Z',
'timestamp': 1662014688000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.mdpi.com/2075-1729/12/3/453'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 3, 19]]},
'references-count': 42,
'journal-issue': {'issue': '3', 'published-online': {'date-parts': [[2022, 3]]}},
'alternative-id': ['life12030453'],
'URL': 'http://dx.doi.org/10.3390/life12030453',
'relation': {},
'ISSN': ['2075-1729'],
'subject': [ 'Paleontology', 'Space and Planetary Science',
'General Biochemistry, Genetics and Molecular Biology',
'Ecology, Evolution, Behavior and Systematics'],
'container-title-short': 'Life',
'published': {'date-parts': [[2022, 3, 19]]}}
